
  
    
      
        Introduction_NNP
        The_DT 5_CD -_: year_NN survival_NN rate_NN for_IN patients_NNS with_IN lung_NN cancer_NN
        is_VBZ approximately_RB 15_CD %_NN ,_, and_CC it_PRP has_VBZ changed_VBN only_RB marginally_RB in_IN
        the_DT last_JJ 30_CD years_NNS [_NN 1_CD ]_NN ._. Tumor_NNP stage_NN is_VBZ the_DT most_RBS significant_JJ
        prognostic_JJ parameter_NN for_IN 5_CD -_: year_NN survival_NN ,_, but_CC even_RB patients_NNS
        with_IN non-small_JJ cell_NN lung_NN cancer_NN (_( non-_NN SCLC_NNP )_) in_IN pathologic_JJ
        stage_NN IA_NNP disease_NN (_( a_DT tumor_NN of_IN less_JJR than_IN 3_CD cm_NN diameter_NN
        located_VBN in_IN one_CD lobe_NN of_IN the_DT lung_NN and_CC more_JJR than_IN 2_CD cm_NN from_IN the_DT
        carina_NN without_IN visceral_NN pleural_NN involvement_NN ,_, atelectasis_NNS ,_,
        or_CC pneumonitis_NNS ,_, and_CC absence_NN of_IN metastatic_JJ spread_NN to_TO
        regional_JJ lymph_NN nodes_NNS )_) have_VBP a_DT 33_CD %_NN chance_NN of_IN recurrence_NN
        within_IN 5_CD years_NNS after_IN complete_JJ surgical_JJ resection_NN (_( lobectomy_NN
        with_IN mediastinal_NN lymph_NN node_NN dissection_NN )_) [_NN 2_CD ]_NN ._. In_IN this_DT group_NN
        of_IN patients_NNS ,_, the_DT tumor_NN most_RBS frequently_RB recurs_NNS at_IN distant_JJ
        sites_NNS ,_, including_VBG the_DT bone_NN ,_, liver_NN ,_, adrenal_NN glands_NNS ,_, and_CC brain_NN
        [_NN 3_CD ]_NN ,_, and_CC the_DT size_NN of_IN the_DT primary_JJ tumor_NN does_VBZ not_RB appear_VB to_TO
        impact_VB on_IN survival_NN [_NN 4_CD ]_NN ._. This_DT suggests_VBZ that_IN even_RB small_JJ and_CC
        seemingly_RB resectable_JJ lung_NN cancers_NNS metastasize_NN early_JJ ._. Data_NNS
        from_IN randomized_JJ screening_NN trials_NNS for_IN lung_NN cancer_NN
        corroborate_VBP this_DT observation_NN ._. In_IN these_DT studies_NNS ,_, more_JJR
        cancers_NNS were_VBD detected_VBN in_IN resectable_JJ stages_NNS ,_, and_CC 5_CD -_: year_NN
        survival_NN rates_NNS were_VBD higher_JJR in_IN the_DT screened_VBD population_NN
        compared_VBN to_TO the_DT control_NN population_NN ,_, but_CC mortality_NN rates_NNS
        (_( total_JJ death_NN rate_NN independent_JJ of_IN time_NN )_) from_IN lung_NN cancer_NN
        were_VBD equal_JJ in_IN both_DT groups_NNS [_NN 5_CD ]_NN ._.
        For_IN this_DT reason_NN ,_, it_PRP is_VBZ important_JJ to_TO develop_VB methods_NNS that_WDT
        will_MD permit_VB facile_NN detection_NN of_IN bronchial_NN mucosal_NN
        abnormalities_NNS that_WDT are_VBP precursors_NNS for_IN lung_NN cancer_NN before_IN
        systemic_JJ shedding_NN of_IN tumor_NN cells_NNS occurs_VBZ ._. Such_JJ precursor_NN
        lesions_NNS can_MD be_VB detected_VBN by_IN sputum_NN cytology_NN and_CC by_IN
        bronchoscopy_NN in_IN large_JJ airways_NNS accessible_JJ by_IN endoscopy_NN ._. They_PRP
        include_VBP metaplasia_NN ,_, dysplasia_NN ,_, and_CC carcinoma_NN 
        in_IN situ_NN (_( CIS_NNP )_) ,_, which_WDT are_VBP thought_VBN to_TO
        represent_VB progressive_JJ histologic_JJ correlates_NNS of_IN
        carcinogenesis_NNS for_IN squamous_JJ cell_NN carcinoma_NN [_NN 6_CD ]_NN ._.
        Current_JJ data_NNS suggest_VBP that_IN 23_CD %_NN of_IN current_JJ and_CC former_JJ
        smokers_NNS have_VBP metaplastic_JJ lesions_NNS ,_, and_CC 2_CD %_NN have_VBP dysplastic_JJ
        lesions_NNS [_NN 7_CD ]_NN ._. However_RB ,_, not_RB all_DT such_JJ lesions_NNS progress_NN to_TO
        lung_NN cancer_NN ._. For_IN instance_NN ,_, smoking_NN cessation_NN ,_, which_WDT can_MD be_VB
        viewed_VBN as_IN a_DT form_NN of_IN active_JJ intervention_NN ,_, appears_VBZ to_TO result_VB
        in_IN a_DT decrease_NN of_IN metaplasia_NN rates_NNS from_IN 27_CD %_NN in_IN active_JJ
        smokers_NNS to_TO 7_CD %_NN in_IN former_JJ smokers_NNS [_NN 7_CD ]_NN ._. It_PRP is_VBZ estimated_VBN that_IN
        approximately_RB 50_CD %_NN of_IN CIS_NNP will_MD progress_VB to_TO invasive_JJ cancer_NN
        over_IN a_DT 6_CD -_: month_NN time_NN period_NN [_NN 8_CD ]_NN ._. However_RB ,_, of_IN 9_CD patients_NNS
        followed_VBN by_IN regular_JJ bronchoscopy_NN at_IN 6_CD -_: month_NN time_NN intervals_NNS ,_,
        4_CD developed_VBN lung_NN cancer_NN at_IN sites_NNS that_WDT had_VBD previously_RB been_VBN
        biopsied_JJ and_CC interpreted_VBN as_IN normal_JJ bronchial_NN epithelium_NN [_NN
        8_CD ]_NN ._. These_DT results_NNS raise_VBP several_JJ important_JJ questions_NNS :_: A_DT )_) Are_VBP
        there_RB determinants_NNS in_IN premalignant_NN lesions_NNS that_WDT predict_VBP
        outcome_NN ,_, i_NNP ._. e_SYM ._. ,_, progression_NN versus_CC regression_NN ?_. B_NNP )_) Are_VBP there_RB
        determinants_NNS in_IN morphologically_RB normal_JJ bronchial_NN mucosa_NN
        that_WDT predict_VBP outcome_NN ?_. C_NNP )_) Can_MD lung_NN cancer_NN arise_VB directly_RB
        from_IN normal_JJ bronchial_NN mucosa_NN or_CC are_VBP histopathologic_JJ
        intermediates_NNS required_VBN ?_.
        To_TO address_VB these_DT questions_NNS ,_, one_CD promising_JJ approach_NN would_MD
        be_VB the_DT development_NN of_IN specific_JJ immunohistochemical_JJ markers_NNS
        capable_JJ of_IN improving_VBG the_DT sensitivity_NN and_CC reliability_NN of_IN
        methods_NNS currently_RB employed_VBN to_TO detect_VB precursor_NN lesions_NNS in_IN
        histologic_JJ and_CC cytologic_JJ specimens_NNS [_NN 9_CD ,_, 10_CD ]_NN ._. Because_IN
        proliferation_NN is_VBZ a_DT requirement_NN for_IN lung_NN cancer_NN development_NN ,_,
        markers_NNS specific_JJ for_IN cell_NN proliferation_NN are_VBP expected_VBN to_TO
        prove_VB useful_JJ ._.
        Two_CD proliferation_NN markers_NNS ,_, proliferating_VBG cell_NN nuclear_JJ
        antigen_NN (_( PCNA_NNP )_) and_CC Ki-_NNP 67_CD ,_, have_VBP been_VBN extensively_RB studied_VBN in_IN
        this_DT context_NN ._. PCNA_NNP is_VBZ a_DT homotrimeric_JJ protein_NN that_IN binds_NNS
        tightly_RB to_TO DNA_NNP and_CC to_TO proteins_NNS involved_VBN in_IN DNA_NNP replication_NN
        and_CC repair_NN ._. It_PRP is_VBZ essential_JJ for_IN DNA_NNP replication_NN and_CC is_VBZ
        found_VBN in_IN all_DT proliferating_VBG cells_NNS ._. However_RB ,_, because_IN PCNA_NNP is_VBZ
        also_RB essential_JJ for_IN several_JJ types_NNS of_IN DNA_NNP repair_NN ,_, it_PRP may_MD be_VB
        present_JJ in_IN non-proliferating_JJ cells_NNS [_NN 11_CD ,_, 12_CD ]_NN ._. Ki-_NNP 67_CD is_VBZ an_DT
        epitope_NN of_IN a_DT nuclear_JJ protein_NN recognized_VBN by_IN the_DT MIB-_NNP 1_CD
        monoclonal_NN antibody_NN ._. The_DT protein_NN is_VBZ frequently_RB expressed_VBN
        throughout_IN the_DT cell_NN cycle_NN of_IN proliferating_VBG cells_NNS ,_, and_CC it_PRP
        has_VBZ not_RB been_VBN detected_VBN in_IN non-proliferating_JJ cells_NNS ._. During_IN
        interphase_NN ,_, Ki-_NNP 67_CD is_VBZ located_VBN primarily_RB in_IN nucleolar_NN and_CC
        peri-nucleolar_JJ regions_NNS ,_, and_CC it_PRP appears_VBZ to_TO be_VB associated_VBN
        with_IN condensed_JJ chromatin_NN [_NN 13_CD ]_NN ._. The_DT function_NN of_IN the_DT Ki-_NNP 67_CD
        protein_NN is_VBZ still_RB unknown_JJ [_NN 14_CD ]_NN ,_, however_RB ,_, it_PRP appears_VBZ to_TO be_VB
        required_VBN for_IN cells_NNS to_TO progress_VB through_IN the_DT cell_NN cycle_NN [_NN 15_CD ,_,
        16_CD ]_NN ._. Immunohistochemical_NNP studies_NNS with_IN PCNA_NNP and_CC Ki-_NNP 67_CD
        indicate_VBP that_IN ,_, in_IN at_IN least_JJS some_DT cases_NNS ,_, increased_VBN lung_NN tumor_NN
        staining_VBG for_IN these_DT markers_NNS correlates_NNS with_IN decreased_VBD
        survival_NN [_NN 17_CD ,_, 18_CD ,_, 19_CD ,_, 20_CD ]_NN ._. These_DT proliferation_NN markers_NNS can_MD
        also_RB be_VB detected_VBN in_IN premalignant_NN lesions_NNS of_IN the_DT lung_NN [_NN 21_CD ,_,
        22_CD ,_, 23_CD ,_, 24_CD ]_NN ._.
        In_IN this_DT report_NN ,_, we_PRP describe_VBP the_DT results_NNS of_IN our_PRP$
        comparison_NN of_IN one_CD of_IN these_DT classic_JJ proliferation_NN markers_NNS ,_,
        Ki-_NNP 67_CD ,_, with_IN a_DT new_JJ proliferation_NN marker_NN ,_, MCM_NNP 2_CD [_NN 25_CD ]_NN ._. MCM_NNP 2_CD is_VBZ
        one_CD of_IN six_CD members_NNS of_IN the_DT minichromosome_NN maintenance_NN (_( MCM_NNP )_)
        protein_NN family_NN ._. These_DT serve_VB as_IN components_NNS of_IN "_'' licensing_NN
        factor_NN ,_, "_'' which_WDT is_VBZ essential_JJ for_IN initiation_NN of_IN DNA_NNP
        replication_NN and_CC for_IN limiting_VBG replication_NN to_TO one_CD round_NN per_IN
        cell_NN cycle_NN [_NN 26_CD ,_, 27_CD ]_NN ._. The_DT MCM_NNP proteins_NNS are_VBP also_RB associated_VBN
        with_IN replication_NN forks_NNS and_CC are_VBP likely_JJ to_TO stimulate_VB the_DT
        unwinding_VBG of_IN the_DT parental_JJ DNA_NNP strands_NNS at_IN these_DT forks_NNS [_NN 28_CD ]_NN ._.
        We_PRP previously_RB demonstrated_VBD [_NN 25_CD ]_NN that_IN ,_, in_IN normal_JJ tissues_NNS ,_,
        MCM_NNP 2_CD is_VBZ detectable_JJ only_RB in_IN proliferating_VBG cells_NNS ._. Not_RB
        surprisingly_RB ,_, it_PRP is_VBZ also_RB present_JJ in_IN a_DT high_JJ proportion_NN of_IN
        cancer_NN cells_NNS ._. Our_PRP$ results_NNS showed_VBD a_DT higher_JJR proportion_NN of_IN
        positively_RB stained_JJ cells_NNS in_IN premalignant_NN breast_NN lesions_NNS
        than_IN with_IN either_DT PCNA_NNP or_CC Ki-_NNP 67_CD [_NN 25_CD ]_NN ._. Others_NNS have_VBP reported_VBN
        similar_JJ results_NNS for_IN MCM_NNP family_NN proteins_NNS compared_VBN with_IN Ki-_NNP 67_CD
        and_CC PCNA_NNP for_IN detection_NN of_IN a_DT variety_NN of_IN premalignant_NN cell_NN
        types_NNS [_NN 29_CD ,_, 30_CD ]_NN ,_, but_CC a_DT comparison_NN of_IN MCM_NNP proteins_NNS with_IN
        Ki-_NNP 67_CD or_CC PCNA_NNP as_IN markers_NNS for_IN premalignant_NN lung_NN lesions_NNS has_VBZ
        not_RB previously_RB been_VBN reported_VBN ._.
      
      
        Methods_NNP
        
          Study_NN population_NN
          MCM_NNP 2_CD and_CC Ki-_NNP 67_CD expression_NN in_IN bronchial_NN biopsy_NN
          specimens_NNS from_IN patients_NNS at_IN risk_NN for_IN lung_NN cancer_NN or_CC with_IN
          suspected_VBN lung_NN cancer_NN were_VBD studied_VBN by_IN
          immunohistochemistry_NN (_( IHC_NNP )_) ._. We_PRP reviewed_VBD all_DT pathology_NN
          specimens_NNS from_IN 106_CD patients_NNS that_WDT had_VBD undergone_VBN
          bronchoscopy_NN with_IN standard_JJ white_JJ light_JJ and_CC laser-induced_JJ
          fluorescence_NN at_IN Roswell_NNP Park_NNP Cancer_NNP Institute_NNP from_IN March_NNP
          1998_CD to_TO March_NNP 2000_CD ._. Fourteen_CD of_IN these_DT 106_CD patients_NNS were_VBD
          selected_VBN for_IN further_JJ analysis_NN based_VBN on_IN the_DT presence_NN of_IN
          abnormal_JJ morphology_NN and_CC the_DT availability_NN of_IN multiple_JJ
          specimen_NN blocks_NNS (_( 4_CD -_: 17_CD per_IN patient_NN )_) for_IN investigations_NNS ._. Of_IN
          these_DT 14_CD patients_NNS ,_, the_DT highest_JJS degree_NN of_IN abnormality_NN in_IN 4_CD
          was_VBD metaplasia_NN ,_, in_IN 4_CD dysplasia_NN ,_, in_IN 3_CD CIS_NNP ,_, in_IN 1_CD invasive_JJ
          squamous_JJ cell_NN carcinoma_NN ,_, and_CC in_IN 2_CD invasive_JJ
          adenocarcinoma_NN ._. Five_CD of_IN these_DT patients_NNS were_VBD Caucasian_NNP
          women_NNS ,_, 1_CD was_VBD an_DT African-_NNP American_JJ man_NN ,_, and_CC 8_CD were_VBD
          Caucasian_NNP men_NNS ._. All_DT were_VBD active_JJ or_CC former_JJ smokers_NNS ._.
        
        
          Sample_NNP preparation_NN and_CC selection_NN
          From_IN each_DT specimen_NN block_NN ,_, 5_CD serial_NN 4_CD -_: Î¼m_NN sections_NNS were_VBD
          cut_VBN and_CC placed_VBN on_IN charged_VBN glass_NN slides_NNS ._. Sections_NNP 1_CD -_: 4_CD were_VBD
          used_VBN for_IN IHC_NNP ,_, and_CC section_NN 5_CD was_VBD stained_JJ with_IN hematoxylin_NN
          and_CC eosin_NN ._. This_DT latter_JJ section_NN was_VBD reviewed_VBN and_CC compared_VBN
          with_IN the_DT original_JJ slide_NN used_VBN for_IN diagnostic_JJ purposes_NNS ._. In_IN
          41_CD specimens_NNS ,_, the_DT morphology_NN was_VBD comparable_JJ between_IN the_DT
          original_JJ slide_NN and_CC slide_NN 5_CD ._. These_DT 41_CD specimens_NNS were_VBD used_VBN
          for_IN IHC_NNP analysis_NN and_CC included_VBD morphologically_RB normal_JJ
          bronchial_NN mucosa_NN ,_, metaplasia_NN ,_, dysplasia_NN ,_, and_CC CIS_NNP (_( see_VB
          Table_NNP 1_CD for_IN the_DT numbers_NNS of_IN specimens_NNS with_IN normal_JJ and_CC
          abnormal_JJ morphology_NN )_) ._.
        
        
          Immunohistochemistry_NNP
          Sections_NNP were_VBD stained_JJ with_IN polyclonal_NN rabbit_NN
          antibodies_NNS raised_VBD and_CC affinity-purified_JJ against_IN the_DT
          N-_NNP terminal_NN portion_NN of_IN MCM_NNP 2_CD [_NN 25_CD ]_NN ._. Parallel_JJ sections_NNS were_VBD
          stained_JJ with_IN the_DT MIB-_NNP 1_CD mouse_NN monoclonal_NN antibody_NN against_IN
          Ki-_NNP 67_CD (_( DAKO_NNP ,_, Carpinteria_NNP ,_, California_NNP )_) ._. IHC_NNP was_VBD performed_VBN
          as_IN described_VBN earlier_JJR [_NN 25_CD ]_NN ._. Briefly_NNP ,_, sections_NNS were_VBD
          deparaffinized_JJ ,_, and_CC those_DT to_TO be_VB stained_JJ with_IN Ki-_NNP 67_CD were_VBD
          subjected_VBN to_TO microwave_NN antigen_NN retrieval_NN in_IN citrate_NN
          buffer_NN for_IN 10_CD minutes_NNS ,_, twice_RB ._. Antigen_NNP retrieval_NN was_VBD not_RB
          required_VBN for_IN MCM_NNP 2_CD ._. MIB-_NNP 1_CD was_VBD used_VBN at_IN a_DT dilution_NN of_IN 1_CD :_: 50_CD ._.
          The_DT MCM_NNP 2_CD antibody_NN was_VBD used_VBN at_IN a_DT dilution_NN of_IN 1_CD :_: 500_CD ._. The_DT
          avidin-biotin_JJ detection_NN method_NN was_VBD employed_VBN on_IN a_DT Ventana_NNP
          Automated_NNP System_NNP (_( Tucson_NNP ,_, Arizona_NNP )_) ._. An_DT irrelevant_JJ rabbit_NN
          antiserum_NN served_VBD as_IN a_DT negative_JJ control_NN ._. Percentage_NN ,_,
          intensity_NN ,_, and_CC distribution_NN of_IN stained_JJ cells_NNS were_VBD
          analyzed_VBN and_CC scored_VBD for_IN each_DT antibody_NN independently_RB by_IN
          two_CD of_IN the_DT authors_NNS (_( DFT_NNP ,_, JAH_NNP )_) with_IN similar_JJ results_NNS ._.
        
        
          Statistical_NNP Analysis_NNP
          The_DT percent_NN of_IN cells_NNS stained_JJ for_IN each_DT sample_NN was_VBD
          estimated_VBN as_IN a_DT continuous_JJ number_NN ranging_VBG from_IN 0_CD to_TO 100_CD ._.
          The_DT staining_VBG intensity_NN was_VBD categorically_RB coded_VBN as_IN 0_CD
          (_( absent_JJ )_) ,_, 1_CD (_( weak_JJ )_) ,_, 2_CD (_( moderate_JJ )_) ,_, or_CC 3_CD (_( strong_JJ )_) ._. The_DT
          average_NN of_IN both_DT the_DT percent_NN of_IN cells_NNS stained_JJ and_CC staining_VBG
          intensity_NN was_VBD calculated_VBN for_IN each_DT type_NN of_IN specimen_NN
          (_( normal_JJ mucosa_NN ,_, metaplasia_NN ,_, dysplasia_NN ,_, CIS_NNP )_) ._. To_TO test_VB for_IN
          differences_NNS between_IN the_DT staining_VBG characteristics_NNS of_IN MCM_NNP 2_CD
          and_CC Ki-_NNP 67_CD both_DT the_DT parametric_JJ paired_VBN samples_NNS t-test_JJ and_CC
          the_DT non-parametric_JJ Wilcoxon_NNP rank-sum_JJ test_NN were_VBD performed_VBN ._.
          To_TO test_VB for_IN differences_NNS across_IN specimen_NN classes_NNS (_( normal_JJ
          mucosa_NN ,_, metaplasia_NN ,_, dysplasia_NN and_CC CIS_NNP )_) for_IN each_DT stain_VB
          (_( Ki-_NNP 67_CD or_CC MCM_NNP 2_LS )_) ,_, the_DT analysis_NN of_IN variance_NN method_NN as_RB well_RB
          as_IN the_DT non-parametric_JJ Kruskal-_NNP Wallis_NNP tests_NNS were_VBD used_VBN ._. To_TO
          test_VB specifically_RB for_IN differences_NNS between_IN dysplasia_NN and_CC
          CIS_NNP for_IN each_DT stain_VB ,_, the_DT independent_JJ samples_NNS t-test_JJ and_CC
          the_DT Mann-_NNP Whitney_NNP tests_NNS were_VBD performed_VBN ._. Both_DT parametric_JJ
          and_CC non-parametric_JJ tests_NNS were_VBD used_VBN because_IN the_DT
          distributional_NN assumptions_NNS required_VBN for_IN parametric_JJ
          testing_NN may_MD not_RB be_VB satisfied_VBN in_IN all_DT cases_NNS ._. All_DT
          statistical_JJ tests_NNS assumed_VBD a_DT two-sided_JJ alternative_NN with_IN a_DT
          5_CD %_NN level_NN of_IN significance_NN ._.
        
      
      
        Results_NNS
        In_IN normal_JJ bronchial_NN mucosa_NN ,_, antibodies_NNS against_IN both_DT
        proteins_NNS ,_, MCM_NNP 2_CD and_CC Ki-_NNP 67_CD ,_, generated_VBD similar_JJ patterns_NNS :_: some_DT
        cells_NNS in_IN the_DT basal_NN and_CC parabasal_NN layer_NN of_IN the_DT bronchial_NN
        epithelium_NN displayed_VBD immunoreactivity_NN (_( Fig_NNP ._. 1_LS )_) ._. The_DT
        proportion_NN of_IN cells_NNS staining_VBG for_IN MCM_NNP 2_CD was_VBD significantly_RB (_( 
        p_NN <_NN 0_CD ._. 02_CD )_) greater_JJR than_IN for_IN Ki-_NNP 67_CD
        (_( Table_NNP 1_LS )_) ._. In_IN both_DT cases_NNS ,_, the_DT intensity_NN of_IN nuclear_JJ staining_VBG
        was_VBD variable_JJ ._.
        In_IN premalignant_NN lesions_NNS ,_, evaluation_NN of_IN the_DT staining_VBG by_IN
        the_DT two_CD antibodies_NNS (_( Table_NNP 1_LS )_) revealed_VBD significantly_RB (_( 
        p_NN <_NN 0_CD ._. 001_CD )_) more_RBR frequent_JJ staining_VBG
        of_IN nuclei_NN within_IN metaplastic_JJ lesions_NNS by_IN antibodies_NNS against_IN
        MCM_NNP 2_CD than_IN by_IN antibodies_NNS against_IN Ki-_NNP 67_CD ._. We_PRP also_RB noticed_VBD
        that_IN ,_, in_IN metaplasia_NN ,_, anti-_NN MCM_NNP 2_CD frequently_RB stained_JJ both_DT
        basal_NN cells_NNS and_CC cells_NNS throughout_IN the_DT entire_JJ thickness_NN of_IN
        the_DT epithelium_NN ,_, while_IN anti-_NN Ki-_NNP 67_CD primarily_RB stained_JJ basal_NN
        cells_NNS and_CC cells_NNS in_IN the_DT lower_JJR half_NN of_IN the_DT epithelium_NN (_( Fig_NNP ._.
        1_LS ,_, lower_JJR of_IN the_DT two_CD "_'' metaplasia_NN "_'' panels_NNS )_) ._. Although_IN the_DT
        number_NN of_IN samples_NNS of_IN dysplasia_NN and_CC CIS_NNP was_VBD too_RB low_JJ to_TO
        permit_VB statistical_JJ evaluation_NN of_IN the_DT differences_NNS between_IN
        the_DT two_CD antibodies_NNS ,_, we_PRP noticed_VBD that_IN in_IN every_DT case_NN of_IN
        dysplasia_NN or_CC CIS_NNP ,_, the_DT frequency_NN of_IN cells_NNS stained_JJ by_IN
        anti-_NN MCM_NNP 2_CD was_VBD as_IN high_JJ or_CC higher_JJR than_IN the_DT frequency_NN of_IN
        staining_VBG by_IN anti-_NN Ki-_NNP 67_CD ._. In_IN fact_NN ,_, the_DT same_JJ relationship_NN was_VBD
        evident_JJ in_IN the_DT normal_JJ mucosa_NN and_CC metaplasia_NN samples_NNS ._.
        Consequently_RB ,_, when_WRB the_DT data_NNS for_IN all_DT 41_CD samples_NNS were_VBD
        combined_VBN ,_, the_DT difference_NN in_IN staining_VBG frequency_NN between_IN
        anti-_NN MCM_NNP 2_CD and_CC anti-_NN Ki-_NNP 67_CD was_VBD highly_RB significant_JJ (_( 
        p_NN <_NN 0_CD ._. 001_CD ;_: Table_NNP 1_LS )_) ._.
        We_PRP observed_VBD variable_JJ staining_VBG in_IN premalignant_NN lesions_NNS ._.
        In_IN many_JJ cases_NNS ,_, within_IN single_JJ lesions_NNS some_DT regions_NNS stained_JJ
        while_IN others_NNS did_VBD not_RB ,_, and_CC the_DT intensity_NN of_IN staining_VBG was_VBD
        variable_JJ from_IN region_NN to_TO region_NN and_CC from_IN cell_NN to_TO cell_NN within_IN
        regions_NNS ._. The_DT level_NN of_IN variability_NN was_VBD similar_JJ for_IN both_DT
        markers_NNS (_( Fig_NNP ._. 1_LS )_) ._.
        In_IN the_DT progression_NN from_IN normal_JJ mucosa_NN to_TO metaplasia_NN to_TO
        dysplasia_NN ,_, the_DT results_NNS obtained_VBN with_IN both_DT antibodies_NNS
        suggested_VBD differences_NNS in_IN staining_VBG frequency_NN and_CC intensity_NN ._.
        For_IN both_DT antibodies_NNS ,_, the_DT mean_NN percentages_NNS of_IN cells_NNS stained_JJ
        and_CC staining_VBG intensity_NN were_VBD different_JJ across_IN specimen_NN
        categories_NNS (_( all_DT 
        p_NN -_: values_NNS <_NN 0_CD ._. 010_CD )_) and_CC increased_VBN
        from_IN normal_JJ mucosa_NN to_TO metaplasia_NN and_CC from_IN metaplasia_NN to_TO
        dysplasia_NN ._. Although_IN the_DT sample_NN numbers_NNS are_VBP too_RB low_JJ to_TO draw_VB
        a_DT firm_JJ conclusion_NN ,_, the_DT data_NNS suggest_VBP a_DT possible_JJ decrease_NN in_IN
        staining_VBG frequency_NN by_IN both_DT antibodies_NNS in_IN the_DT transition_NN
        from_IN dysplasia_NN to_TO CIS_NNP (_( 
        p_NN =_SYM 0_CD ._. 117_CD for_IN Ki-_NNP 67_CD and_CC 
        p_NN =_SYM 0_CD ._. 080_CD for_IN MCM_NNP 2_LS )_) (_( Table_NNP 1_LS )_) ._.
        No_DT significant_JJ differences_NNS were_VBD detected_VBN between_IN the_DT
        average_JJ stain_VB intensities_NNS produced_VBN by_IN the_DT two_CD antibodies_NNS
        (_( Fig_NNP ._. 1_LS ;_: Table_NNP 1_LS )_) ._.
      
      
        Discussion_NNP
        This_DT is_VBZ the_DT first_JJ comparison_NN of_IN MCM_NNP 2_CD and_CC Ki-_NNP 67_CD
        expression_NN in_IN premalignant_NN lesions_NNS of_IN the_DT human_JJ lung_NN ,_, and_CC
        it_PRP showed_VBD that_IN MCM_NNP 2_CD was_VBD expressed_VBN in_IN a_DT greater_JJR percentage_NN
        of_IN cells_NNS in_IN normal_JJ mucosa_NN and_CC in_IN premalignant_NN lesions_NNS than_IN
        Ki-_NNP 67_CD ._. The_DT proportion_NN of_IN cells_NNS stained_JJ for_IN MCM_NNP 2_CD ranged_VBD from_IN
        5_CD %_NN to_TO 100_CD %_NN and_CC for_IN Ki-_NNP 67_CD from_IN 1_CD %_NN to_TO 60_CD %_NN (_( Table_NNP 1_LS )_) ._. The_DT
        average_JJ percentage_NN of_IN cells_NNS stained_JJ for_IN MCM_NNP 2_CD (_( 11_CD -_: 64_CD %_NN )_) was_VBD
        higher_JJR than_IN that_DT for_IN Ki-_NNP 67_CD (_( 3_CD -_: 34_CD %_NN )_) ._. Statistical_NNP analyses_NNS of_IN
        the_DT frequencies_NNS of_IN positively_RB stained_JJ cells_NNS were_VBD done_VBN with_IN
        the_DT paired_VBN samples_NNS t-test_JJ and_CC the_DT Wilcoxon_NNP sign_NN rank_NN test_NN ._.
        Both_DT tests_NNS showed_VBD a_DT striking_JJ difference_NN (_( 
        p_NN <_NN 0_CD ._. 001_CD )_) in_IN immunoreactivity_NN
        between_IN these_DT markers_NNS across_IN all_DT 41_CD samples_NNS ._. This_DT finding_VBG
        suggests_VBZ that_IN MCM_NNP 2_CD may_MD prove_VB to_TO be_VB a_DT more_RBR sensitive_JJ
        intermediate_JJ marker_NN for_IN lung_NN cancer_NN risk_NN than_IN Ki-_NNP 67_CD ._.
        However_RB ,_, there_EX are_VBP several_JJ caveats_NNS to_TO the_DT use_NN of_IN MCM_NNP 2_CD
        for_IN assessing_VBG lung_NN cancer_NN risk_NN ._. Most_JJS importantly_RB ,_, the_DT
        ability_NN of_IN cells_NNS to_TO proliferate_VBP ,_, even_RB though_IN a_DT hallmark_NN of_IN
        malignancy_NN ,_, is_VBZ also_RB a_DT component_NN of_IN inflammation_NN and_CC
        healing_NN ._. Thus_RB ,_, metaplastic_JJ lesions_NNS are_VBP frequently_RB
        associated_VBN with_IN chronic_JJ inflammation_NN as_IN exemplified_VBN by_IN the_DT
        presence_NN of_IN such_JJ lesions_NNS in_IN 27_CD %_NN of_IN current_JJ smokers_NNS but_CC only_RB
        7_CD %_NN of_IN former_JJ smokers_NNS [_NN 7_CD ]_NN ._. Furthermore_RB ,_, even_RB high-grade_JJ
        dysplasia_NN does_VBZ not_RB necessarily_RB lead_VB to_TO invasive_JJ cancer_NN [_NN
        8_CD ]_NN ._. The_DT fact_NN that_DT anti-_NN MCM_NNP 2_CD more_RBR frequently_RB stains_NNS
        metaplastic_JJ cells_NNS at_IN the_DT epithelial_NN surface_NN suggests_VBZ that_IN
        it_PRP is_VBZ more_RBR likely_JJ than_IN anti-_NN Ki-_NNP 67_CD to_TO detect_VB exfoliated_JJ
        proliferating_VBG epithelial_NN cells_NNS in_IN cytological_JJ specimens_NNS
        such_JJ as_IN sputum_NN ._. However_RB ,_, this_DT presumably_RB higher_JJR sensitivity_NN
        for_IN premalignant_NN cells_NNS could_MD be_VB accompanied_VBN by_IN an_DT
        unacceptably_RB low_JJ specificity_NN ._. Therefore_RB ,_, it_PRP is_VBZ important_JJ to_TO
        assess_VB the_DT positive_JJ predictive_JJ value_NN of_IN both_DT markers_NNS ,_, MCM_NNP 2_CD
        and_CC Ki-_NNP 67_CD ,_, for_IN lung_NN cancer_NN risk_NN in_IN cytologic_JJ and_CC histologic_JJ
        specimens_NNS from_IN a_DT defined_VBN population_NN at_IN risk_NN for_IN this_DT
        disease_NN in_IN a_DT prospective_JJ study_NN ._.
        Second_JJ ,_, there_EX has_VBZ been_VBN a_DT shift_NN in_IN the_DT predominant_NN type_NN
        of_IN lung_NN cancer_NN from_IN squamous_JJ cell_NN carcinoma_NN to_TO
        adenocarcinoma_NN in_IN the_DT United_NNP States_NNPS over_IN the_DT past_JJ twenty_CD
        years_NNS [_NN 4_CD ,_, 31_CD ]_NN ._. Since_IN adenocarcinomas_NNS predominantly_RB arise_VBP
        in_IN the_DT periphery_NN of_IN the_DT lung_NN and_CC less_RBR frequently_RB in_IN the_DT
        larger_JJR and_CC more_RBR easily_RB accessible_JJ airways_NNS ,_, the_DT utility_NN of_IN
        assessing_VBG morphological_JJ ,_, molecular_JJ ,_, and_CC proliferative_JJ
        changes_NNS in_IN these_DT larger_JJR airways_NNS may_MD be_VB called_VBN into_IN
        question_NN ._. During_IN the_DT 1970_CD s_VBZ three_CD randomized_JJ lung_NN cancer_NN
        screening_NN trials_NNS were_VBD conducted_VBN in_IN the_DT US_NNP ,_, and_CC each_DT of_IN
        these_DT trials_NNS used_VBD sputum_NN cytology_NN as_IN one_CD of_IN the_DT means_NNS to_TO
        detect_VB lung_NN cancer_NN at_IN an_DT early_JJ stage_NN [_NN 32_CD ,_, 33_CD ,_, 34_CD ]_NN ._. Aside_RB
        from_IN the_DT major_JJ finding_NN that_DT screening_NN did_VBD not_RB reduce_VB lung_NN
        cancer_NN mortality_NN ,_, several_JJ other_JJ important_JJ facts_NNS were_VBD
        uncovered_VBN ._. These_DT included_VBD the_DT findings_NNS that_WDT lung_NN cancers_NNS
        detected_VBN by_IN sputum_NN cytology_NN only_RB ,_, compared_VBN to_TO chest_NN X-_NNP ray_NN
        only_RB ,_, had_VBD a_DT higher_JJR rate_NN of_IN complete_JJ resectability_NN (_( 83_CD %_NN vs_NNS ._.
        62_CD %_NN )_) and_CC a_DT higher_JJR 5_CD -_: year_NN survival_NN rate_NN (_( 80_CD %_NN vs_NNS ._. 40_CD %_NN )_) [_NN 33_CD ]_NN ;_:
        that_IN approximately_RB one-third_NN of_IN the_DT cancers_NNS detected_VBN by_IN
        sputum_NN cytology_NN were_VBD adenocarcinomas_NNS and_CC two-thirds_NNS were_VBD
        squamous_JJ cell_NN carcinomas_NNS [_NN 32_CD ]_NN ;_: that_DT sputum_NN cytology_NN
        detected_VBD 36_CD %_NN of_IN all_DT incident_NN cases_NNS of_IN lung_NN cancer_NN
        (_( excluding_VBG interval_NN cases_NNS )_) [_NN 32_CD ]_NN ;_: and_CC that_DT sputum_NN cytology_NN
        detected_VBD 6_CD /_NN 40_CD adenocarcinomas_NNS [_NN 32_CD ]_NN ._. It_PRP can_MD thus_RB be_VB
        concluded_VBN that_IN cytological_JJ examination_NN of_IN sputum_NN specimens_NNS
        is_VBZ able_JJ to_TO detect_VB adenocarcinomas_NNS at_IN an_DT early_JJ stage_NN albeit_IN
        with_IN low_JJ sensitivity_NN (_( 15_CD %_NN )_) ._. Staining_NNP of_IN sputum_NN specimens_NNS
        for_IN proliferation_NN markers_NNS ,_, such_JJ as_IN MCM_NNP 2_CD and_CC Ki-_NNP 67_CD ,_, may_MD
        increase_VB that_DT sensitivity_NN by_IN focusing_VBG the_DT pathologist_NN 's_POS
        attention_NN on_IN proliferating_VBG cells_NNS ._. In_IN addition_NN to_TO its_PRP$
        potential_JJ for_IN detecting_VBG frank_JJ malignancy_NN ,_, staining_VBG for_IN
        proliferation_NN markers_NNS may_MD also_RB provide_VB an_DT estimate_NN of_IN the_DT
        frequency_NN of_IN potentially_RB precancerous_JJ conditions_NNS
        (_( metaplasia_NN and_CC dysplasia_NN )_) in_IN the_DT patient_NN 's_POS airways_NNS ._. This_DT
        estimate_NN may_MD be_VB helpful_JJ for_IN determining_VBG whether_IN to_TO initiate_VB
        other_JJ more_RBR costly_JJ evaluations_NNS for_IN lung_NN cancer_NN
        detection_NN ._.
        Third_NNP ,_, since_IN MCM_NNP 2_CD and_CC Ki-_NNP 67_CD are_VBP both_DT markers_NNS of_IN cellular_JJ
        proliferation_NN and_CC required_VBN for_IN cell_NN cycle_NN progression_NN [_NN 15_CD ,_,
        16_CD ,_, 26_CD ,_, 27_CD ,_, 28_CD ]_NN ,_, the_DT fact_NN that_DT anti-_NN MCM_NNP 2_CD stained_JJ a_DT larger_JJR
        number_NN of_IN cells_NNS than_IN anti-_NN Ki-_NNP 67_CD in_IN every_DT specimen_NN examined_VBD
        suggests_VBZ that_IN Ki-_NNP 67_CD may_MD be_VB expressed_VBN during_IN a_DT shorter_JJR
        interval_NN of_IN the_DT cell_NN cycle_NN than_IN MCM_NNP 2_CD ._. MCM_NNP 2_CD is_VBZ present_JJ
        throughout_IN the_DT cell_NN cycle_NN [_NN 35_CD ]_NN ,_, while_IN Ki-_NNP 67_CD is_VBZ
        predominantly_RB expressed_VBN during_IN S_NNP ,_, G_NNP 2_CD and_CC M_NNP phase_NN ._.
        Variability_NNP of_IN cell_NN cycle_NN time_NN in_IN mammalian_JJ cells_NNS is_VBZ
        largely_RB a_DT result_NN of_IN differences_NNS in_IN the_DT duration_NN of_IN G_NNP 1_CD
        phase_NN ._. Thus_RB ,_, specimens_NNS that_WDT consist_VBP of_IN a_DT relatively_RB slow_JJ
        growing_VBG population_NN of_IN cells_NNS and_CC consequently_RB a_DT higher_JJR
        proportion_NN of_IN cells_NNS in_IN G_NNP 1_CD phase_NN would_MD show_VB staining_VBG of_IN more_JJR
        cells_NNS with_IN MCM_NNP 2_CD than_IN Ki-_NNP 67_CD ._. Conversely_RB ,_, specimens_NNS with_IN
        cells_NNS dividing_VBG at_IN a_DT high_JJ rate_NN would_MD show_VB staining_VBG of_IN near_IN
        equal_JJ numbers_NNS of_IN cells_NNS for_IN MCM_NNP 2_CD and_CC Ki-_NNP 67_CD ._. Thus_RB it_PRP is_VBZ
        likely_JJ that_IN staining_VBG for_IN both_DT ,_, MCM_NNP 2_CD and_CC Ki-_NNP 67_CD ,_, will_MD provide_VB
        information_NN about_IN cell_NN cycle_NN distribution_NN and_CC possibly_RB
        growth_VB dynamics_NNS not_RB obtainable_JJ by_IN staining_VBG for_IN either_DT
        marker_NN alone_RB ._.
        Finally_RB ,_, the_DT data_NNS presented_VBN on_IN MCM_NNP 2_CD expression_NN by_IN IHC_NNP
        were_VBD obtained_VBN with_IN affinity-purified_JJ polyclonal_NN rabbit_NN
        antibodies_NNS ._. The_DT supply_NN of_IN these_DT purified_JJ antibodies_NNS is_VBZ
        limited_VBN ,_, and_CC their_PRP$ use_NN for_IN MCM_NNP 2_CD immunostaining_VBG is_VBZ therefore_RB
        not_RB uniformly_RB available_JJ ._. Although_IN additional_JJ polyclonal_NN
        antibody_NN preparations_NNS can_MD be_VB generated_VBN by_IN immunizing_VBG more_JJR
        rabbits_NNS ,_, the_DT best_JJS solution_NN would_MD be_VB the_DT commercial_JJ
        availability_NN of_IN specific_JJ MCM_NNP 2_CD monoclonal_NN antibodies_NNS ._.
        Fortunately_RB ,_, several_JJ of_IN these_DT are_VBP now_RB available_JJ and_CC useful_JJ
        for_IN Western_NNP blotting_VBG and_CC staining_VBG of_IN frozen_VBN sections_NNS ._. The_DT
        utility_NN of_IN these_DT antibodies_NNS for_IN IHC_NNP in_IN paraffin-embedded_JJ
        specimens_NNS is_VBZ being_VBG investigated_VBN ._.
      
      
        Conclusion_NNP
        We_PRP have_VBP confirmed_VBN that_DT polyclonal_NN anti-_NN MCM_NNP 2_CD antibodies_NNS
        provide_VBP consistent_JJ ,_, reliable_JJ staining_VBG in_IN routinely_RB fixed_VBN
        tissues_NNS without_IN a_DT requirement_NN for_IN antigen_NN retrieval_NN ._.
        Results_NNS obtained_VBN are_VBP easy_JJ to_TO interpret_VB ,_, since_IN there_EX is_VBZ a_DT
        striking_JJ difference_NN between_IN normal_JJ bronchoepithelium_NN and_CC
        premalignant_NN lesions_NNS ._. Thus_RB MCM_NNP 2_CD is_VBZ an_DT easy-to-use_JJ marker_NN ,_,
        which_WDT has_VBZ great_JJ potential_NN for_IN assessment_NN of_IN progression_NN and_CC
        regression_NN of_IN morphologically_RB abnormal_JJ lesions_NNS in_IN future_JJ
        primary_JJ lung_NN cancer_NN prevention_NN studies_NNS and_CC for_IN the_DT early_JJ
        detection_NN of_IN lung_NN cancer_NN in_IN screening_NN studies_NNS ._.
      
      
        Competing_VBG Interests_NNP
        None_NNP Declared_NNP
      
    
  
